Your browser is no longer supported. Please, upgrade your browser.
Reviva Pharmaceuticals Holdings, Inc.
Index- P/E- EPS (ttm)-1.11 Insider Own40.25% Shs Outstand17.23M Perf Week-2.22%
Market Cap47.34M Forward P/E- EPS next Y-0.84 Insider Trans0.00% Shs Float6.48M Perf Month-5.63%
Income-3.90M PEG- EPS next Q-0.28 Inst Own18.60% Short Float1.82% Perf Quarter-15.99%
Sales- P/S- EPS this Y-622.00% Inst Trans-1.96% Short Ratio1.81 Perf Half Y-29.74%
Book/sh1.86 P/B1.89 EPS next Y4.40% ROA- Target Price13.00 Perf Year-67.71%
Cash/sh0.65 P/C5.38 EPS next 5Y- ROE- 52W Range3.29 - 15.10 Perf YTD-59.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.69% Beta-
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low6.99% ATR0.27
Employees5 Current Ratio6.60 Sales Q/Q- Oper. Margin- RSI (14)45.42 Volatility7.83% 7.23%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.89 Prev Close3.65
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume65.29K Price3.52
Recom2.00 SMA20-4.22% SMA50-6.64% SMA200-25.98% Volume58,247 Change-3.56%
Nov-16-21 10:40AM  
Nov-15-21 08:15AM  
Sep-15-21 08:30AM  
Sep-02-21 08:30AM  
Aug-25-21 06:00AM  
Aug-16-21 08:15AM  
Jun-28-21 07:00AM  
Jun-21-21 06:50PM  
May-26-21 08:43PM  
May-17-21 08:21AM  
Apr-26-21 12:33PM  
Apr-14-21 06:23AM  
Apr-01-21 11:45AM  
Mar-22-21 08:26AM  
Mar-11-21 05:36PM  
Mar-04-21 05:00PM  
Jan-19-21 04:40AM  
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VEDANTA PARTNERS, LLC10% OwnerJun 01Buy3.751,330,0004,987,500931,000Jun 03 05:31 PM